First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) Short Interest Up 127.1% in April

First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH – Get Free Report) saw a significant increase in short interest in the month of April. As of April 30th, there was short interest totaling 26,983 shares, an increase of 127.1% from the April 15th total of 11,879 shares. Approximately 3.0% of the company’s shares are sold short. Based on an average daily trading volume, of 10,674 shares, the days-to-cover ratio is presently 2.5 days.

First Trust Nasdaq Pharmaceuticals ETF Price Performance

Shares of FTXH stock opened at $33.87 on Friday. The firm has a market cap of $30.48 million, a PE ratio of 14.51 and a beta of 0.47. The company has a 50-day moving average of $34.01 and a two-hundred day moving average of $33.42. First Trust Nasdaq Pharmaceuticals ETF has a 1-year low of $24.86 and a 1-year high of $35.61.

Get First Trust Nasdaq Pharmaceuticals ETF alerts:

First Trust Nasdaq Pharmaceuticals ETF Cuts Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 31st. Shareholders of record on Thursday, March 26th were paid a dividend of $0.0573 per share. This represents a $0.23 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend was Thursday, March 26th.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. NBC Securities Inc. boosted its stake in First Trust Nasdaq Pharmaceuticals ETF by 33.0% during the fourth quarter. NBC Securities Inc. now owns 1,325 shares of the company’s stock worth $44,000 after buying an additional 329 shares during the period. Kestra Advisory Services LLC purchased a new stake in shares of First Trust Nasdaq Pharmaceuticals ETF in the 4th quarter valued at $59,000. Raymond James Financial Inc. purchased a new stake in shares of First Trust Nasdaq Pharmaceuticals ETF in the 2nd quarter valued at $57,000. Flagship Harbor Advisors LLC purchased a new stake in shares of First Trust Nasdaq Pharmaceuticals ETF in the 4th quarter valued at $205,000. Finally, Flputnam Investment Management Co. purchased a new stake in shares of First Trust Nasdaq Pharmaceuticals ETF in the 4th quarter valued at $230,000.

About First Trust Nasdaq Pharmaceuticals ETF

(Get Free Report)

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.

Read More

• Five stocks we like better than First Trust Nasdaq Pharmaceuticals ETF
• Viking Sails to All-Time Highs—Fundamentals Signal More to Come
• Datavalut Gains Traction: 5 Reasons to Sell Now
• TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
• The Power Grid Is Dying—Is It Time to Buy Its Replacement?

Receive News & Ratings for First Trust Nasdaq Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for First Trust Nasdaq Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.